Prime Peptides

Testing methods

Not publicly disclosed.

Testing lab

Not publicly disclosed.

Most recent COA

Not publicly posted.

OpenAssay score ↗

— pending integration with openassay.org.

• Testing transparency

  12/40

  Public 7-category testing rubric grade plus disclosed testing methods plus a named third-party lab. The full range is gated on the vendor publicly naming the tests they run; a high rubric grade without disclosure caps at 18 of 40.

• Operational & regulatory standing

  6/25

  Reflects FDA actions, payment-processor issues, ownership uncertainty, closures, and editorial audit notes the vendor-risk monitor has surfaced. A recent published COA earns a small bonus on top of the operational base.

• Operational stability

  15/15

  Vendor age. 5+ years of operation earns full points; 1 year or less earns minimal credit. Absent foundedYear earns a neutral default; absence of data is not proof of risk.

• Verification tier

  10/10

  Editorial tier assignment based on documentation completeness, response to corrections, and presence of verifiable business address. Tier 1 vendors meet the highest bar.

• Price discipline

  10/10

  Heuristic check on aggressive discounting. Reasonable codes (<=25%) earn full points; 25-40% earns half; >40% off list often signals inventory clearance or churn and earns zero.

Prime Peptides has operated since 2019 but carries an active FDA warning letter regarding 2024 GLP-1 marketing claims, surfaced as a watch-status flag on the Pepticker risk monitor. The D grade of 53 reflects the open regulatory matter, not the underlying catalog or pricing posture. The vendor remains operational and is retained on the directory for transparency. The Trust Score is built from a 12-of-40 testing component (no public testing-method disclosure), a 6-of-25 regulatory standing (watch status with audit notes), the maximum 15-of-15 stability bonus, and the full 10-of-10 tier and price-discipline components. The 16-point shortfall against the next-lowest tier-1 entry is concentrated entirely in the regulatory column. The watch-flag persists until the FDA matter is materially resolved or supplanted by newer disclosures. Buyers evaluating Prime Peptides should review the FDA warning letter directly and weigh it against the vendor's seven-year operational history. The 10% discount code (PRIME10) is conservative; pricing posture has not shifted materially since the 2024 letter was issued. Prime Peptides is not frequently cross-shopped within the tier-1 set as of May 2026; the FDA flag dominates buyer comparisons.

Editorial rationale tying the Trust Score to component evidence. Send corrections to corrections@pepticker.com.